我们建立了第一个前瞻性队列,以了解登革热病毒感染如何受到载体特异性决定因素的影响,例如对埃及伊蚊唾液蛋白的体液免疫。
2-9岁儿童在其监护人知情同意的情况下被纳入PAGODAS(登革热和唾液伊蚊儿科评估组)队列。每半年对儿童进行一次登革热抗体和Ae蛋白抗体随访。使用酶联免疫吸附测定和登革热特异性中和滴度进行埃及伊蚊唾液腺匀浆。在任何时候出现发烧的儿童进行登革热测试。
从2018年7月13日至8月30日,我们注册了771名儿童。在基线,22%(173/770)具有针对一种或更多种登革热血清型的中和抗体的证据。到2020年4月,51名儿童患有有症状的登革热,而148名未接受登革热的儿童患有通过中和测定定义的表观登革热。在多变量模型中,对Ae具有较高抗体的个体。埃及伊蚊唾液蛋白感染登革热的可能性是其1.5倍(危险比[HR],1.47[95%置信区间{CI},1.05-2.06];P=.02),特别是患有不明显登革热的人(HR,1.64[95%CI,1.12-2.41];P=0.01)。
Ae的高水平血清阳性。埃及伊蚊唾液蛋白与登革热感染的未来发展有关,主要是不明显的,天真的柬埔寨儿童的登革热。
NCT03534245。
We established the first prospective cohort to understand how infection with dengue virus is influenced by vector-specific determinants such as humoral immunity to Aedes aegypti salivary proteins.
Children aged 2-9 years were enrolled in the PAGODAS (Pediatric Assessment Group of Dengue and Aedes Saliva) cohort with informed consent by their guardians. Children were followed semi-annually for antibodies to dengue and to proteins in Ae. aegypti salivary gland homogenate using enzyme-linked immunosorbent assays and dengue-specific neutralization titers. Children presented with fever at any time for dengue testing.
From 13 July to 30 August 2018, we enrolled 771 children. At baseline, 22% (173/770) had evidence of neutralizing antibodies to 1 or more dengue serotypes. By April 2020, 51 children had symptomatic dengue while 148 dengue-naive children had inapparent dengue defined by neutralization assays. In a multivariate model, individuals with higher antibodies to Ae. aegypti salivary proteins were 1.5 times more likely to have dengue infection (hazard ratio [HR], 1.47 [95% confidence interval {CI}, 1.05-2.06]; P = .02), particularly individuals with inapparent dengue (HR, 1.64 [95% CI, 1.12-2.41]; P = .01).
High levels of seropositivity to Ae. aegypti salivary proteins are associated with future development of dengue infection, primarily inapparent, in dengue-naive Cambodian children.
NCT03534245.